Rhythm Biosciences Ltd. announced positive progress with respect to its platform technology expansion program. Background: A key focus within the Company's Strategic Plan is to identify opportunities to leverage the core cancer detection capabilities within a platform expansion program. The key lead biomarker for Rhythm's initial bowel cancer product, ColoSTAT, provides a strong catalyst to progress new activities for the early detection of a range of other cancers.

Platform Expansion - Targeting Five Additional Cancers Following Rhythm's announcement that it would target five additional cancer diagnostics, the Company formally commenced a research and development program earlier this year that included a detailed and robust biomarker review. The review included sophisticated analysis of thousands of biomarkers with the outcome resulting in Rhythm having identified leading biomarkers for each of the outline target cancers: Breast, Lung, Cervical, Pancreatic and Gastric. Some of the biomarkers identified appear to be common between cancer types.

With the first phase of the expansion program complete, Rhythm is now focused on accelerating the next stage of feasibility, testing and validation of the biomarkers of interest. To progress these activities appropriately and enable the team to continue to focus upon ColoSTAT, the Company has engaged the services of Agilex Biolabs under an agreement to support feasibility, validation and development works associated with the platform technology expansion program for one initial cancer target. Agilex is Australia's largest and most technologically advanced bioanalytical and toxicology laboratory with 25 years' experience providing a comprehensive suite of bioanalytical services to biotech and pharmaceutical companies - with a particular focus and expertise in oncology.

They were acquired earlier this year by Australian healthcare and pathology company Healius Limited which further supports Rhythm's desire to partner with best-in-class operators within the healthcare sector.